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I n Japan,  the prevalence of lifestyle-related illnesses such as hypertension and dyslipidemia is high,  and 
the two conditions are often seen in combination.  The 
use of antihypertensive medications or 3-hydroxy- 
3-methylglutaryl coenzyme A reductase inhibitors 
(statins) has become fundamental therapy in the man-
agement of patients with hypertension or dyslipidemia 
to prevent future cardiovascular events [1 , 2].  In gen-
eral,  chronic disease management requires the use of 
multiple medications,  and the majority of patients are 
on two or more medications for optimal treatment.
Although a compound-pill therapy of amlodipine- 
atorvastatin is available for patients with hypertension 
and dyslipidemia,  there are very few reports concerning 
the benefits of this single-pill therapy for concomitant 
hypertension and dyslipidemia [3].
The purpose of this study was to determine whether 
switching from treatment with amlodipine and atorvas-
tatin using 2 pills to an equivalent treatment using a 
single pill would be useful in Japanese outpatients.
Materials and Methods
Subjects. We retrospectively reviewed data 
obtained from 94 outpatients for whom treatment with 
amlodipine and atorvastatin using two pills was switched 
to an equal dose of single-pill therapy (Caduet®) in 11 
hospitals (Aki General Hospital,  Chikamori Hospital,  
Hosogi Hospital,  Japanese Red Cross Kochi Hospital,  
Kochi Prefectural Hata Kenmin Hospital,  Kohoku 
Hospital,  Niyodo Hospital,  Ooida Hospital,  Susaki 
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This study examined whether switching from amlodipine and atorvastatin treatment using two pills to an equal 
dose of single-pill therapy is useful in Japanese outpatients.  We retrospectively reviewed data obtained from 94 
outpatients for whom treatment with two pills,  namely amlodipine and atorvastatin,  was switched to an equal 
dose of single-pill therapy in 11 hospitals.  The criterion for enrollment in this study was that patients had 
switched their medication without changing other anti-hypertensive or anti-cholesterol drugs.  Neither systolic 
nor diastolic blood pressure changed significantly after switching to an equal dose of single-pill therapy,  
whereas low-density lipoprotein (LDL) cholesterol levels significantly decreased after the medication was 
switched from 94 ± 24 mg/dl to 89 ± 17 mg/dl (p= 0.015).  A switch from medication with two separate pills of 
amlodipine and atorvastatin to an equal dose of single-pill therapy resulted in an overall decrease in LDL cho-
lesterol.  The results indicated that the switch to single-pill therapy might be a useful treatment.
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Kurosio Hospital,  Tosa Municipal Hospital,  and Kochi 
Medical School Hospital) from January 2010 to 
December 2013.  The criteria for enrollment in this 
study were patients who switched to single-pill therapy 
that dispensed an equivalent amount of medication 
without changing other antihypertensive or anticholes-
terol drugs and who underwent serial daytime blood 
pressure measurements in an outpatient clinic or serial 
blood examinations for cholesterol values within at least 
12 months before and after switching medications.  A 
total of 94 patients were enrolled as the subjects of this 
study.  The study was approved by the Ethics Committee 
on Medical Research of Kochi Medical School Hospital 
(ERB-100411).
Clinical evaluation. Evaluation of the patients 
included obtaining a medical history,  blood pressure 
measurements,  laboratory data (total cholesterol and 
low-density lipoprotein (LDL) cholesterol),  and 
detailed questions about the prescription and the actual 
conditions under which they took their medicine.  We 
assessed the changes in blood pressure values and cho-
lesterol levels from the baseline to the first evaluation 
after the medications were switched.  To evaluate the 
factors responsible for lowering LDL cholesterol levels,  
the patients were divided into 2 groups.  Patients whose 
LDL cholesterol levels were lower than before they 
switched medications were classified as having lowered 
LDL cholesterol levels.  Patients whose LDL cholesterol 
levels were the same as or higher than before switching 
medications were classified as not having lowered LDL 
cholesterol levels.
Data analysis. All data are expressed as means±SD 
or frequencies (percentages).  Differences in continuous 
variables were assessed using Student’s t-test.  Pearson’s 
chi-square test was used for comparisons between 
non-continuous variables,  and Fisher’s exact test was 
used when the expected frequency was lower than 5.  
Statistical significance was defined as p < 0.05.  Statistical 
analysis was performed using SPSS (version 14.0J) sta-
tistical software (SPSS Inc.,  Chicago,  IL,  USA).
Results
Study population. The data for 94 outpatients 
with a mean age of 72 ± 10 years were retrospectively 
analyzed.  About half of the patients (51%) were men.  
Thirty-six patients had diabetes mellitus,  34 had coro-
nary heart disease,  and 21 had a history of stroke.  Most 
patients (n = 89) were treated with Caduet® #4 
(amlodipine at 5 mg/day and atorvastatin at 10 mg/day),  
while 1 patient was treated with Caduet® #1 (amlodip-
ine at 2.5 mg/day and atorvastatin at 5 mg/day),  3 
patients were treated with Caduet® #2 (amlodipine at 
2.5 mg/day and atorvastatin at 10 mg/day) and 1 
patient was treated with Caduet® #3 (amlodipine at 
5 mg/day and atorvastatin at 5 mg/day).
Changes in blood pressure and cholesterol values.
Figure 1A shows the changes in blood pressure in 86 of 
the 94 patients during a follow-up period of 71 ± 45  
days.  Neither systolic nor diastolic blood pressure 
changed significantly after switching to an equal dose of 
single-pill therapy.  As shown in Fig. 1B,  although the 
total cholesterol levels only changed from 175 ± 34  
mg/dl to 171 ± 24 mg/dl (p = 0.231) (n = 66,  follow-up 
period of 159 ± 105 days),  the LDL cholesterol levels 
significantly decreased after switching from 94 ± 24  
mg/dl to 89 ± 17 mg/dl of medication (p= 0.015) (n = 78,  
follow-up period of 160 ± 106 days).
Factors responsible for lowering LDL cholesterol 
levels. As shown in Table 1,  the patients with low-
ered LDL cholesterol levels were younger than the 
patients without lowered levels.  There were fewer dia-
betes mellitus patients in the group with lowered LDL 
cholesterol levels.
Figure 2 shows the distribution of ages and changes 
in LDL cholesterol levels after switching to an equal 
dose of single-pill therapy.  There seemed to be different 
patterns among the different age groups (middle age,  
elderly,  and very elderly).  Figure 3 shows the changes 
in LDL cholesterol levels for the patients < 60 years old 
(n = 12; Fig. 3A),  60-74 years old (n = 34; Fig. 3B) and 
≥ 75 years old (n = 32; Fig. 3C).  The LDL cholesterol 
levels significantly decreased in patients aged < 60 years 
and patients aged ≥ 75 years old.  On the other hand,  
patients aged 60-74 years did not show significant 
changes in LDL cholesterol levels.
When the patients were divided into 2 groups,  
namely those with and without diabetes mellitus,  the 
LDL cholesterol levels were significantly decreased in 
the patients without diabetes mellitus (n = 48) from 
97 ± 21 mg/dl to 89 ± 16 mg/dl (p < 0.01),  whereas the 
levels in the patients with diabetes mellitus (n = 29) only 
changed from 89 ± 30 mg/dl to 88 ± 20 mg/dl (p = 0.802) 
(Figs. 4A and 4B).
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Fig. 1　 The changes in blood pressure (A) and cholesterol (B).  Data are shown as means±SD.
Table 1　 Factors responsible for lowering LDL cholesterol levels after switching the medication
Patients without lowered LDL levels
(n＝29)
Patients with lowered LDL levels
(n＝49) p-value
Sex: Male,  n 12 (41%) 27 (55%) 0.241
Age,  years 75±9 70±1 0.034
75≤ years old,  n 13 (45%) 19 (39%) 0.599
Prescription dates,  days 52±20 52±20 0.965
The kinds number of medications,  n 6±3 6±3 0.576
The timing for taking statin: morning,  n 19 (66%) 27 (55%) 0.422
Diabetes mellitus,  n 15 (52%) 14 (29%) 0.048
Coronary heart disease,  n 13 (45%) 15 (31%) 0.230
History of stroke,  n 5 (17%) 8 (16%) 1.000
Data are shown as the means±standard deviation or number (%).  LDL,  low-density lipoprotein.
Discussion
The aim of this study was to determine whether 
switching from treatment with amlodipine and atorvas-
tatin using 2 pills to an equal dose of single-pill therapy 
is useful for the treatment of patients without consider-
ation of bias due to the efficacy of the medication.
In this study,  there was no significant change in sys-
tolic or diastolic blood pressure after the therapy was 
switched.  This is thought to be because the patients 
monitored their blood pressure at home and had 
obtained information on high blood pressure from var-
ious sources,  and were thus knowledgeable about 
hypertension and motivated to take the medication.
On the other hand,  LDL cholesterol levels decreased 
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Fig. 2　 The distribution of ages and changes in LDL cholesterol 
levels.
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Fig. 3　 The changes in LDL cholesterol levels in patients (A) ＜60 
years old,  (B) 60-74 years old,  and (C) ≥75 years old.  Data are 
shown as means±SD.
significantly after the medication was switched.  
Although we did not assess medication adherence in 
this study,  these results might have been caused by an 
improvement in adherence to the medication.  A previ-
ous study reported that adherence to anti-dyslipidemia 
drugs is poor [4].  Although the precise reason for this 
is unclear,  it might be that patients have no subjective 
symptoms,  and cholesterol levels cannot be easily mea-
sured by patients themselves like blood pressure levels 
[5-7].  Polypharmacy and the complexity of the treat-
ment regimen are known to be important determinants 
of poor medication adherence [8].  Ellis et al.  reported 
that younger age (less than 65 years) was one of the fac-
tors associated with nonadherent behavior in patients 
treated with a statin [9].  Thus,  the switch to single-pill 
therapy might have improved the adherence to medica-
tion in our subjects.
Moreover,  our study showed that LDL cholesterol 
levels decreased significantly in patients without diabe-
tes mellitus but not in patients with diabetes mellitus.  
Although it has been reported that adherence to medi-
cation decreases in patients with diabetes mellitus 
[10 , 11],  in our study we speculated that patients with 
diabetes mellitus,  like patients with hypertension,  rec-
ognized their disease and were highly aware of the need 
to prevent future cardiovascular events,  and thus might 
have shown good adherence to their medication regi-
men.
In our study,  the kinds of and number of medica-
tions used before switching were not factors that 
reduced the LDL cholesterol level after the switch to 
single-pill therapy.  The timing with which the statins 
were taken (for example,  after breakfast or after dinner) 
was also not a factor in reducing the LDL cholesterol 
level.  Patients tend to disregard the importance of 
statins compared to other medications such as antihy-
pertensive drugs and drugs for diabetes,  and the fact 
that the LDL cholesterol level decreased after switching 
to single-pill therapy suggests that switching the medi-
cation improved adherence.
In this study,  no additional dietary and/or physical 
therapy instructions were given other than the directive 
to switch therapies.  In other words,  this study was a 
retrospective study in which the only intervention was 
the switching of drugs.  Teramoto et al.  reported the 
necessity of diet therapy for patients with dyslipidemia 
regardless of whether LDL-C lowering drugs are pre-
scribed [12].  The effects of low- and moderate-intensity 
exercise on LDL levels should not be ignored,  because 
low- to moderate-aerobic exercise intensities have shown 
a positive effect on LDL subfractions [13].  Therefore,  
different results might be obtained if dietary and/or 
physical therapy were combined with the switching of 
medications.
While our study could have some significant bene-
fits,  it also has some limitations.  First,  it was a retro-
spective study conducted in a small number of hospi-
tals.  A multivariate analysis was not used to evaluate 
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Fig. 4　 The changes in LDL cholesterol levels in patients (A) without diabetes mellitus and (B) with diabetes mellitus.  Data are shown 
as means±SD.
the factors responsible for lowering LDL cholesterol 
levels because of the small sample numbers.  Second,  
some data such as data on triglycerides,  non-high-den-
sity lipoprotein cholesterol (non-HDLC),  and serum 
lipid levels were not obtained.  Elevated non-HDLC 
levels are a significant risk factor for the development of 
atherothrombotic infarction as well as coronary heart 
diseases,  but they reduce the risk of cardioembolic 
infarction in the general Japanese population [14].  
Third,  medication adherence was not assessed by an 
objective index such as the proportion of days covered,  
and cognitive function in the elderly patients was not 
assessed in this study.  Finally,  some reports have 
shown that statins increase the risk of new-onset diabe-
tes mellitus in a dose-dependent manner [15 , 16].  We 
consider new diabetes mellitus onset due to statins to be 
an adverse event requiring considerable attention.  
However,  this study did not analyze if there were any 
changes in HbA1c after statin adherence was improved.
In conclusion,  a switch from treatment with 
amlodipine and atorvastatin using two separate pills to 
an equal dose of single-pill therapy resulted in an over-
all decrease in LDL cholesterol.  The results suggested 
that the switch to single-pill therapy might be a useful 
treatment.
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